Connor, Clark & Lunn Investment Management Ltd. Protalix Bio Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$1.34 - $1.85 $129,371 - $178,610	-96,546 Reduced 57.63%	70,990 $126,000
Q3 2023 Nov 13, 2023	BUY	$1.49 - $2.02 $77,475 - $105,033	51,997 Added 45.0%	167,536 $278,000
Q2 2023 Aug 10, 2023	SELL	$2.0 - $3.36 $86,328 - $145,031	-43,164 Reduced 27.2%	115,539 $231,000
Q1 2023 May 09, 2023	BUY	$1.37 - $2.16 $217,423 - $342,798	158,703 New	158,703 $333,000

Others Institutions Holding PLX

# of Institutions

Shares Held

3.58M

Call Options Held

61.1K

Put Options Held

36.2K

Jim Simons Renaissance Technologies LLC | New York, Ny

956K
Shares

$1.67 Million
0.0% of portfolio
Gsa Capital Partners LLP London, X0

435K
Shares

$761,622
0.03% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

374K
Shares

$654,074
0.0% of portfolio
Black Rock Inc. New York, NY

333K
Shares

$583,049
0.0% of portfolio
Stratos Wealth Partners, Ltd.

270K
Shares

$472,500
0.0% of portfolio

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $87.1M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account